News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DNAPrint Pharmaceuticals Completes The Development Of A Second Assay For Its Anemia Drug


8/4/2006 12:25:25 PM

DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that KBI BioPharma, Inc., has completed and validated a second analytical method for PT-401, based on SDS-PAGE, a well established separation technique that will be used for in-process analysis, release and stability testing for its PT-401 anemia drug, which is being developed by its subsidiary, DNAPrint Pharmaceuticals, Inc.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES